Order a test
News

Multi-cancer blood test can detect 26 cancers

In the first study of its kind, researchers have used a simple blood test to safely detect multiple cancers in nearly 10,000 women with undiagnosed cancer. In some cases, women who took the blood test were able to have treatment to potentially cure the cancer. The researchers at the Johns Hopkins Kimmel Cancer Center in […]

Read more
News

RGCC Investigates Potential Treatments and Tests for COVID-19

As the world tries to cope with the rise in cases of covid-19 during the coronavirus pandemic, drug companies are racing to develop treatments that could reduce the number of deaths from the illness. This includes the specialist medical genetic testing company RGCC, which has turned its expertise and technology in the diagnosis and treatment […]

Read more
News

Blood test shows promise in detecting 50 cancers

Researchers have developed a blood test that can detect more than 50 common and deadly cancers, often before symptoms appear. The test could be especially useful in 12 cancers it was most accurate at detecting. These included pancreatic cancer, which is often only diagnosed at a very late stage and has poor outcomes and survival. […]

Read more
News

New test could spot early signs of prostate cancer

Researchers have used genetic testing to detect the very early changes that occur in the tumours of men with prostate cancer. Researchers at the University College London (UCL) Cancer Institute say the new type of blood test will help them understand the genetic characteristics of the tumours that cause prostate cancer, which is the second […]

Read more
News

Study shows genetic changes can occur years before diagnosis

A study suggests the genetic changes that cause cancers can happen years or even decades before the disease is diagnosed. A large analysis by an international team of researchers revealed that many DNA mutations – the changes in our genome that can trigger a tumour to develop – can occur long before someone is diagnosed […]

Read more
News

Circulating tumour DNA tests predictive in pancreatic cancer

More evidence is emerging to support the use of testing for circulating tumour DNA (ctDNA) as a promising way to predict whether a cancer will come back. Tumours release degraded fragments of DNA, including ctDNA, into the bloodstream. Testing a cancer patient’s blood for this DNA, using a type of blood test called a liquid […]

Read more
News

Liquid biopsy potential to guide colorectal cancer treatment

In the future, liquid biopsy testing is likely to play an increasing role in identifying which patients with colorectal cancer are most likely to have their cancer come back again after surgery. Liquid biopsy testing could also help doctors to decide which treatments would be most suitable to recommend to individual patients, according to new […]

Read more
News

Top prize in the international iGEM Synthetic Biology competition 2019

We are happy to announce that we contributed to iGem Thessaloniki team’s won of the top prize in the international iGEM Synthetic Biology competition 2019, organized by MIT University in Boston. The project is called “POSEIDON” and it is a toolkit for the examination of DNA-Protein interactions. IGem team of Thessaloniki deploys the first DNA […]

Read more
News

Liquid biopsy option for advanced lung cancer patients

Liquid biopsy tests could be an option for patients with a form of lung cancer, according to the early results of research presented at a major cancer conference. A growing number of patients with advanced lung cancer could soon be offered a blood test to help to decide the best treatment for them instead of […]

Read more
News

Launch of RGCC CAMBISeq® and RGCC CeFSeq

In as little as two weeks, patients and clinicians can gain access to a next-generation genetic test provided by RGCC that can analyse the sequence of both DNA and RNA. The RGCC CAMBISeq® (Cancer Analysis, Mutational Burden and Instability Sequencing) test sequences DNA and RNA – the nucleic acids that carry genomic sequence information and […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more